GCGR E63 Cell line

The Glioma Cellular Genetics Resource (GCGR) is a panel of primary, patient-derived IDH-wildtype glioblastoma stem-like models, offering a biologically relevant system to capture inter-patient heterogeneity in tumour growth, behaviour, and molecular features.

Contributors

Inventor Institute
Gillian Morrison, Steven Pollard University of Edinburgh
Product description: GCGR‑E63 is a primary, patient‑derived, IDH‑wildtype glioblastoma stem‑like cell line derived from human tumour tissue. The line grows as an adherent, laminin‑dependent monolayer, has a doubling time of approximately 106 hours, and is tumourigenic in vivo. Early‑passage transcriptomic profiling (P3) indicated a Classical‑like transcriptional state based on probability scoring. The line shows a development‑like gene expression phenotype with low enrichment for mesenchymal‑immune (MESImm) gene programmes.
Gender: Male
Production details: Derived from surgically resected primary glioblastoma tissue and expanded as an adherent monolayer under laminin supported condition
Additional notes: This cell line is a primary glioblastoma stem‑like model derived from a single patient tumour and exhibits intrinsic cellular heterogeneity, reflecting the diversity and plasticity typical of glioblastoma. Transcriptional state classifications were assessed at early passage (P3) and may change in culture
Cat. #: 140084
Tool sub type: Primary
Cancer types: Brain cancer
Organism: Human
Tissue: Glioblastoma
Gender: Male
Model: Primary cell line
Morphology: Adherent monolayer with stem-like features (SOX2, NESTIN).
Growth properties: Adherent
Cancer Types In Detail: Glioblastoma
Format: Frozen
Growth medium: Serum‑free DMEM/HAMS‑F12 (“Complete + EFL”) supplemented with glucose, NEAA, B27, N2, BSA, beta‑mercaptoethanol, Pen/Strep, and recombinant EGF (10 ng/mL), FGF‑2 (10 ng/mL), plus laminin‑1 (2 ug/mL). Laminin is required for adherent growth.
Subculture routine: Passage at 80–90% confluence; split 1:4–1:6; detach using Accutase; avoid over‑dilution; replace medium weekly
Recommended controls: GCGR human neural stem cell lines
Biosafety level: 2
References:

Pollard SM et al. Cell Stem Cell 2009 PMID: 19497285.

Furqan M et al. Pharmaceutics 2025 PMID: 40430842.

Elliott R et al. A comprehensive pharmacological survey across heterogeneous patient‑derived GBM stem cell models. bioRxiv

2025.

Images

View Gallery

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.